Type 1 Diabetes — Deal Benchmarks & Valuation
Market Analysis
Type 1 Diabetes is one of the most actively transacted indications in metabolic licensing. Phase 2 deals for type 1 diabetes carry a median total deal value of $3.2B, with upfront payments ranging from $369M to $963M. The recommended deal structure allocates approximately 21% to upfront payments and 79% to milestones.
Milestone structures for type 1 diabetes deals allocate $453M to development milestones, $553M to regulatory milestones, and $1.5B to commercial milestones. Royalty rates range from 14.5% to 26.6% at the base tier, with tiered escalation reaching 18.5%-30.6% on peak sales.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What are typical deal terms for type 1 diabetes licensing?
What royalty rates are standard for type 1 diabetes deals?
How are type 1 diabetes deal milestones structured?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.